On July 20, 2022 Singapore-based biotech start-up, Tetris Therapeutics Pte. Ltd. reported that it has changed its name to Axcynsis Therapeutics Pte. Ltd (Press release, Axcynsis Therapeutics, JUL 20, 2022, View Source [SID1234618243]).. The new name will better reflect the company’s core business and platform technology – AXC (Antibody-X Conjugate) Synthesis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Antibody Drug Conjugates (ADCs) are a class of anticancer agents designed by conjugating cytotoxic drugs to monoclonal antibodies." said Dr. Zou Bin, founder and CEO of Axcynsis Therapeutics. "In fact, this concept can be extended beyond cytotoxic drugs. Hence we are developing our platform technologies to synthesize Antibody-X Conjugates, where "X" could be any molecules that disrupt the abnormal cells."

Axcynsis Therapeutics will continue to strengthen the company’s pipeline and provide new treatment options to address unmet medical needs.